About 90% of the people in the world carry a latent virus known to cause cancer. On the fiftieth anniversary of its discovery, researchers are considering joining up their experimental treatments against these malignancies. David Holmes reports.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study
Signal Transduction and Targeted Therapy Open Access 12 January 2021
-
EBV based cancer prevention and therapy in nasopharyngeal carcinoma
npj Precision Oncology Open Access 15 May 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Epstein, M.A., Achong, B.G. & Barr, Y.M. Lancet 283, 702–703 (1964).
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monogr. Eval. Carcinog. Risks Hum. 100 (Pt. B), 49–92 (2012).
Bollard, C.M. et al. J. Clin. Oncol. 32, 798–808 (2014).
Hui, E.P. et al. Cancer Res. 73, 1676–1688 (2013).
Sokal, E.M. et al. J. Infect. Dis. 196, 1749–1753 (2007).
Cohen, J.I., Fauci, A.S., Varmus, H. & Nabel, G.J. Sci. Transl. Med. 3, 107fs7 (2011).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holmes, D. The cancer-virus cures. Nat Med 20, 571–574 (2014). https://doi.org/10.1038/nm0614-571
Published:
Issue date:
DOI: https://doi.org/10.1038/nm0614-571
This article is cited by
-
Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study
Signal Transduction and Targeted Therapy (2021)
-
EBV based cancer prevention and therapy in nasopharyngeal carcinoma
npj Precision Oncology (2017)
